BR112019020967A2 - métodos e reagentes para analisar interfaces de proteína-proteína - Google Patents
métodos e reagentes para analisar interfaces de proteína-proteína Download PDFInfo
- Publication number
- BR112019020967A2 BR112019020967A2 BR112019020967-0A BR112019020967A BR112019020967A2 BR 112019020967 A2 BR112019020967 A2 BR 112019020967A2 BR 112019020967 A BR112019020967 A BR 112019020967A BR 112019020967 A2 BR112019020967 A2 BR 112019020967A2
- Authority
- BR
- Brazil
- Prior art keywords
- optionally substituted
- protein
- presenting
- compound
- target protein
- Prior art date
Links
- 0 CC1(*)N(*)*C(*)=C1* Chemical compound CC1(*)N(*)*C(*)=C1* 0.000 description 18
- RJBZCUHXVBADMO-UHFFFAOYSA-N CC(C)(C)OC(CS(CCCl)(=O)=O)=O Chemical compound CC(C)(C)OC(CS(CCCl)(=O)=O)=O RJBZCUHXVBADMO-UHFFFAOYSA-N 0.000 description 2
- QHLPPNXQZWGHAY-UHFFFAOYSA-N CC(C)C(C(NC(Cc1cccc(O)c1)C(N(CCC1)NC1C(OC(C)C)=O)=O)=O)NC=O Chemical compound CC(C)C(C(NC(Cc1cccc(O)c1)C(N(CCC1)NC1C(OC(C)C)=O)=O)=O)NC=O QHLPPNXQZWGHAY-UHFFFAOYSA-N 0.000 description 1
- VSPKPANARHVSQP-UHFFFAOYSA-N CC(C)C(CCC1C)OC1(C(C(N(CCCC1)C1C(OC(C)C(C)CC(CCC(C1O)O)C1O)=O)=O)=O)O Chemical compound CC(C)C(CCC1C)OC1(C(C(N(CCCC1)C1C(OC(C)C(C)CC(CCC(C1O)O)C1O)=O)=O)=O)O VSPKPANARHVSQP-UHFFFAOYSA-N 0.000 description 1
- PSKJJVHMLOJCGJ-UHFFFAOYSA-N CC(C)C(CCC1C)OC1(C(C(N(CCCC1)C1C(OC(C)C(C)CC(CCC1O)CC1O)=O)=O)=O)O Chemical compound CC(C)C(CCC1C)OC1(C(C(N(CCCC1)C1C(OC(C)C(C)CC(CCC1O)CC1O)=O)=O)=O)O PSKJJVHMLOJCGJ-UHFFFAOYSA-N 0.000 description 1
- NUABTBILIQFSBS-UHFFFAOYSA-N CC(C)C(CCC1C)OC1(C(C(N(CCCC1)C1C(OC(C)C(C)CC(CCC1O)CC1OC)=O)=O)=O)O Chemical compound CC(C)C(CCC1C)OC1(C(C(N(CCCC1)C1C(OC(C)C(C)CC(CCC1O)CC1OC)=O)=O)=O)O NUABTBILIQFSBS-UHFFFAOYSA-N 0.000 description 1
- DUOLOJQTQAOGLV-HFMPRLQTSA-N CC(C)[C@@H](C(N[C@@H](Cc1cc(O)ccc1)C(N(CCC1)N[C@@H]1C(O)=O)=O)=O)NC(CCSSc1ncccc1)=O Chemical compound CC(C)[C@@H](C(N[C@@H](Cc1cc(O)ccc1)C(N(CCC1)N[C@@H]1C(O)=O)=O)=O)NC(CCSSc1ncccc1)=O DUOLOJQTQAOGLV-HFMPRLQTSA-N 0.000 description 1
- NCWXBUQXXQCTRZ-UHFFFAOYSA-N CC(CCCSSCCN(C)C)=O Chemical compound CC(CCCSSCCN(C)C)=O NCWXBUQXXQCTRZ-UHFFFAOYSA-N 0.000 description 1
- UZMTUCMJPNPGHQ-UHFFFAOYSA-N CCC(C)(C)C(C(N(CCCC1)C1C(OC(CCc(cc1)cc(OC)c1OC)c1cccc(C(C)C)c1)=O)=O)=O Chemical compound CCC(C)(C)C(C(N(CCCC1)C1C(OC(CCc(cc1)cc(OC)c1OC)c1cccc(C(C)C)c1)=O)=O)=O UZMTUCMJPNPGHQ-UHFFFAOYSA-N 0.000 description 1
- AXRLELITXMKHFY-UHFFFAOYSA-N CCC(C)(C)C(C(N(CCCC1)C1C(OC1CC1)=O)=O)=O Chemical compound CCC(C)(C)C(C(N(CCCC1)C1C(OC1CC1)=O)=O)=O AXRLELITXMKHFY-UHFFFAOYSA-N 0.000 description 1
- DZGOJGDINJPFTF-KAWNSFPOSA-N CCC(C)(C)C(C(N(CCCC1)[C@@H]1C(OC(C)(CCc(cc1)cc(OC)c1OC)c1cccc(NC(CSSC)=O)c1)=O)=O)=O Chemical compound CCC(C)(C)C(C(N(CCCC1)[C@@H]1C(OC(C)(CCc(cc1)cc(OC)c1OC)c1cccc(NC(CSSC)=O)c1)=O)=O)=O DZGOJGDINJPFTF-KAWNSFPOSA-N 0.000 description 1
- MBEUZJVBPOGHSD-INIZCTEOSA-N CCC(C)(C)C(C(N(CCCC1)[C@@H]1C(OCC(NCCSSc1ncccc1)=O)=O)=O)=O Chemical compound CCC(C)(C)C(C(N(CCCC1)[C@@H]1C(OCC(NCCSSc1ncccc1)=O)=O)=O)=O MBEUZJVBPOGHSD-INIZCTEOSA-N 0.000 description 1
- CODSCSZHYOGQDG-IBGZPJMESA-N CCC(C)(C)C(C(N(CCCC1)[C@@H]1C(OCCCC(NCCCSSc1ccccn1)=O)=O)=O)=O Chemical compound CCC(C)(C)C(C(N(CCCC1)[C@@H]1C(OCCCC(NCCCSSc1ccccn1)=O)=O)=O)=O CODSCSZHYOGQDG-IBGZPJMESA-N 0.000 description 1
- YUMCRXLLWKQDJY-UHFFFAOYSA-N CCCNC(CC)=O Chemical compound CCCNC(CC)=O YUMCRXLLWKQDJY-UHFFFAOYSA-N 0.000 description 1
- QHJMLMLZGQEMQK-ABEKHUEESA-N CC[C@@H](C(N(C)CC(N(C)CC(N[C@@H](CCCCNC(CCCSSc1ncccc1)=O)C(N(C)CC(NCC(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)C/C=C/C)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O Chemical compound CC[C@@H](C(N(C)CC(N(C)CC(N[C@@H](CCCCNC(CCCSSc1ncccc1)=O)C(N(C)CC(NCC(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)C/C=C/C)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O QHJMLMLZGQEMQK-ABEKHUEESA-N 0.000 description 1
- FNEWXGILCPLSPG-PTDDNHMLSA-N CC[C@@H](C(N(C)CC(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)C/C=C/CCC(NCCSSc2ccccn2)=O)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O Chemical compound CC[C@@H](C(N(C)CC(N(C)[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N(C)[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@H](C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](CC(C)C)C(N(C)[C@@H](C(C)C)C(N(C)[C@H]1[C@@H]([C@H](C)C/C=C/CCC(NCCSSc2ccccn2)=O)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O FNEWXGILCPLSPG-PTDDNHMLSA-N 0.000 description 1
- HZZAVMBKBIZRPU-UHFFFAOYSA-N CN(C)CCSSCCCC(O)=O Chemical compound CN(C)CCSSCCCC(O)=O HZZAVMBKBIZRPU-UHFFFAOYSA-N 0.000 description 1
- LNJMHEJAYSYZKK-UHFFFAOYSA-N Cc1ncccn1 Chemical compound Cc1ncccn1 LNJMHEJAYSYZKK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482018P | 2017-04-05 | 2017-04-05 | |
| US62/482,018 | 2017-04-05 | ||
| PCT/US2018/026014 WO2018187423A1 (en) | 2017-04-05 | 2018-04-04 | Methods and reagents for analyzing protein-protein interfaces |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019020967A2 true BR112019020967A2 (pt) | 2020-05-05 |
Family
ID=63712343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019020967-0A BR112019020967A2 (pt) | 2017-04-05 | 2018-04-04 | métodos e reagentes para analisar interfaces de proteína-proteína |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20210285955A1 (enExample) |
| EP (1) | EP3607326A4 (enExample) |
| JP (2) | JP2020520988A (enExample) |
| KR (2) | KR20240093922A (enExample) |
| CN (1) | CN110785428A (enExample) |
| AU (2) | AU2018250186B2 (enExample) |
| BR (1) | BR112019020967A2 (enExample) |
| CA (1) | CA3058964A1 (enExample) |
| IL (1) | IL269779B1 (enExample) |
| WO (1) | WO2018187423A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116478132A (zh) | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| CA3078565A1 (en) | 2017-10-12 | 2019-04-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| AU2019401466B2 (en) * | 2018-12-21 | 2025-04-24 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
| CA3159559A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN114867735A (zh) | 2019-11-04 | 2022-08-05 | 锐新医药公司 | Ras抑制剂 |
| KR20250175006A (ko) | 2019-11-04 | 2025-12-15 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN119661684B (zh) * | 2024-10-21 | 2025-11-25 | 山东大学 | 一种高抗炎活性的脂联素突变体及其制备方法与应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999010373A1 (en) * | 1997-08-26 | 1999-03-04 | Wisconsin Alumni Research Foundation | Non-immunosuppressive cyclosporins and their use in the prevention and treatment of hiv infection |
| US7220552B1 (en) * | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
| US7176037B2 (en) * | 2000-07-13 | 2007-02-13 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
| US8324262B2 (en) * | 2005-12-20 | 2012-12-04 | The Brigham And Women's Hospital, Inc. | Tricyclic necrostatin compounds |
| CN101351550B (zh) * | 2006-01-03 | 2012-10-10 | 霍夫曼-拉罗奇有限公司 | 具有卓越的伴侣和折叠活性的嵌合融合蛋白 |
| US20090054334A1 (en) * | 2007-05-23 | 2009-02-26 | Mutz Mitchell W | Combinatorial improvement of bifunctional drug properties |
| US9428845B1 (en) * | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| US9260484B2 (en) * | 2011-06-15 | 2016-02-16 | Ohio State Innovation Foundation | Small molecule composite surfaces as inhibitors of protein-protein interactions |
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| US10427131B2 (en) * | 2015-03-19 | 2019-10-01 | 3M Innovative Properties Company | Guanidine-functionalized perlite particles, articles containing the particles, and methods of using the particles and articles |
| US9989535B2 (en) * | 2015-10-01 | 2018-06-05 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| CN105902537A (zh) * | 2016-04-26 | 2016-08-31 | 兰州大学 | 靶向人fkbp51蛋白的先导化合物及其筛选方法与应用 |
| EP3606492A4 (en) * | 2017-04-05 | 2020-11-11 | Revolution Medicines, Inc. | LINKS INVOLVED IN A COOPERATIVE BINDING AND USES THEREOF |
-
2018
- 2018-04-04 WO PCT/US2018/026014 patent/WO2018187423A1/en not_active Ceased
- 2018-04-04 CA CA3058964A patent/CA3058964A1/en active Pending
- 2018-04-04 EP EP18781381.1A patent/EP3607326A4/en active Pending
- 2018-04-04 KR KR1020247017424A patent/KR20240093922A/ko not_active Ceased
- 2018-04-04 CN CN201880037176.0A patent/CN110785428A/zh active Pending
- 2018-04-04 US US16/500,634 patent/US20210285955A1/en not_active Abandoned
- 2018-04-04 BR BR112019020967-0A patent/BR112019020967A2/pt unknown
- 2018-04-04 KR KR1020197032295A patent/KR20200003802A/ko not_active Ceased
- 2018-04-04 AU AU2018250186A patent/AU2018250186B2/en active Active
- 2018-04-04 JP JP2020504095A patent/JP2020520988A/ja active Pending
-
2019
- 2019-10-03 IL IL269779A patent/IL269779B1/en unknown
-
2023
- 2023-06-21 JP JP2023101616A patent/JP7781821B2/ja active Active
-
2024
- 2024-02-22 US US18/584,357 patent/US20240426833A1/en active Pending
- 2024-11-19 AU AU2024266705A patent/AU2024266705A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200003802A (ko) | 2020-01-10 |
| WO2018187423A1 (en) | 2018-10-11 |
| IL269779A (en) | 2019-11-28 |
| AU2024266705A1 (en) | 2024-12-12 |
| JP2020520988A (ja) | 2020-07-16 |
| JP2023134482A (ja) | 2023-09-27 |
| CN110785428A (zh) | 2020-02-11 |
| US20210285955A1 (en) | 2021-09-16 |
| EP3607326A4 (en) | 2020-11-18 |
| CA3058964A1 (en) | 2018-10-11 |
| AU2018250186A1 (en) | 2019-11-14 |
| EP3607326A1 (en) | 2020-02-12 |
| US20240426833A1 (en) | 2024-12-26 |
| KR20240093922A (ko) | 2024-06-24 |
| AU2018250186B2 (en) | 2024-12-05 |
| IL269779B1 (en) | 2025-12-01 |
| JP7781821B2 (ja) | 2025-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250085291A1 (en) | Methods and reagents for analyzing protein-protein interfaces | |
| US20240426833A1 (en) | Methods and reagents for analyzing protein-protein interfaces | |
| US20250206715A1 (en) | Compounds that participate in cooperative binding and uses thereof | |
| US20220143202A1 (en) | Compounds that participate in cooperative binding and uses thereof | |
| KR20250116016A (ko) | 화합물, 복합체 및 이들의 제조 및 사용 방법 | |
| HK40100567A (en) | Methods and reagents for analyzing protein-protein interfaces |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |